Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
4 Results for "
c-Fms-IN-1
" in MedChemExpress (MCE) Product Catalog:
Products (4)
4 Results for "c-Fms-IN-1" in MCE Product Catalog:
Cat. No.: HY-18791
CAS No.: 885703-64-0
Target:
Research Areas:
c-Fms-IN-1 is a FMS kinase inhibitor with an IC50 of 0.0008 μM [1].
Synonyms: TPX-0022; CSF1R-IN-2
Target:
Research Areas:
Elzovantinib (TPX-0022) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively .
Target:
Research Areas:
c-Fms-IN-3 is an orally active c-Fms (CSF1R) kinase inhibitor (IC50 = 0. 8 nM). c-Fms-IN-3 inhibits CSF1R kinase activity and reduces macrophage populations. c-Fms-IN-3 reduces bone erosion, pannus invasion, cartilage damage, and inflammation in collagen (HY-NP003)-induced arthritis mouse model. c-Fms-IN-3 is useful for arthritis research [1] .
Cat. No.: HY-111787R
CAS No.: 2271119-26-5
Synonyms: TPX-0022 (Standard); CSF1R-IN-2 (Standard)
Target:
Research Areas:
Elzovantinib (Standard) is the analytical standard of Elzovantinib (HY-111787). This product is intended for research and analytical applications. Elzovantinib (TPX-0022) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
